Roger Williams Medical Center, Providence, RI
Is Roger Williams Medical Center registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does Roger Williams Medical Center hold a Rhode Island pharmacy license?
State board of pharmacy records for Rhode Island are not checked: this index has not yet added that board’s records.
Has Roger Williams Medical Center had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 untitled letter (Mar 18, 2021), 1 state handoff letter (Nov 29, 2021) and 1 FMD-145 letter (Nov 29, 2021) for Roger Williams Medical Center. State board of pharmacy records for Rhode Island are not checked: this index has not yet added that board’s records. The state referral and handoff letters above are FDA’s letters to the state, not board actions.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Roger Williams Medical Center
- Location
- Providence, RI
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 1
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Nov 29, 2021
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 7 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Roger Williams Medical Center, a 503A facility, with 4 dated actions.
| Document | |||
|---|---|---|---|
| Nov 29, 2021 | State handoff letter | State Handoff Letter Issued 11/29/2021 | Not linked by FDA |
| Nov 29, 2021 | FMD-145 letter | FMD-145 Letter Issued 11/29/2021 | Not linked by FDA |
| Mar 18, 2021 | Untitled letter | Untitled Letter Issued (3/18/2021) | FDA copy (archived) |
| Aug 14, 2019 | Form 483 | 483 Issued 08/14/2019 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 7 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Jul 22, 2019 to Aug 14, 2019: 7 observations
- Firm on the cover
- Roger Williams Medical Center, 50 Maude St , Oncology Pharmacy Clinic, Providence, RI 02908-4325
- FEI number
- 3013662663
- Establishment type on the cover
- Producer of Sterile Drugs
- FDA district office on the cover
- One Montvale Avenue Stoneham, MA 02180
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (Internet Archive copy FDA links)
Observation 1
You did not make adequate product evaluation and take remedial action where actionable microbial contamination was found to be present in an area adjacent to the ISO 5 classified aseptic processing area during aseptic production.
Specifically, you failed to present any documentation that the pharmacy has adequately investigated or taken remedial action to control objectionable organisms found in the ISO 7 Clean rooms.
A. Routine environmental monitoring done during production on 5/13/2019, resulted in an airborne viable recovery of 2 CFU/m3 of "Irpex (mold)" in the Chemo Room. You received the May 2019 environmental monitoring report on 5/21/2019 and you did not respond to the excursion until a <Redacted B4> of the Chemo Room was performed on 5/24/2019. You continued to produce in the ISO 5 hoods from 5/21/2019 to 5/23/2019 before performing of the Chemo Room. For example, you produced the chemotherapy treatments Carboplatin 623 MG in NS 250 MLS and frinotecan 300 MG IV D5W500 on 5/21/2019 and Oxaliplatin 160 MG in D5W 250 MLS on 5/22/2019. You did not investigate the root cause of the excursion and assess the potential impact on drug products produced during that period.
B. ...
Observation 2
Your facility design allowed the influx of poor quality air into a higher classified area.
Specifically,
A. There is an the unclassified pharmacy area and the ISO 7 classified Clean Room the unclassified pharmacy area and the ISO 7 classified Chemo Room. Components used in were observed to be cluttered with papers, supplies and equipment. You do not have information or data to provide assurance that the unclassified air from the pharmacy area is not entering the ISO 7 classified Clean Room and Chemo Room though the <Redacted B4> during production.
B. You do not monitor the pressure differential between the ISO 7 Ante Room and the ISO 7 Chemo Room. On 07/22/2019, it was observed that the differential pressme gauge between the two rooms was not operating properly, and the needle on the pressure gauge was resting on the pin below the pressure gauge's minimum scale reading of 0.0 inches of water <Redacted B4> . You have also been documenting a reading of -0.01 inches of water as the pressure reading between the ISO 7 Chemo Room and ISO 7 Ante Room on your tQJIQ)"Temperature, Humidity, and Pressure Log," which is a reading below the capability of your differential pressure gauge. ...
Observation 3
Your facility was designed and/or operated in a way that permits poor flow of personnel.
Specifically, the design of your facility requires personnel to <Redacted B4> Room, where <Redacted B4> are produced, into the <Redacted B4> Room <Redacted B4> are produced. Production personnel were observed during the inspection producing hazardous drug products in one of the <Redacted B4> BSCs located in Room, and then moving into the -Room to produce nonhazardous drug products in the LFH without changing all of their gowning materials. The design of the facility creates the potential for cross contamination of non-hazardous materials and hazardous materials when personnel Room.
Observation 4
Disinfecting agents and cleaning pads used in the ISO 5 classified aseptic processing areas were not sterile.
Specifically, you use non-sterile, low lint pads to wipe down all drug component containers, packaging materials and production equipment with sterile, <Redacted B4> prior to placing these items into the <Redacted B4> ISO 5 Biological Safety Cabinets (BSCs) and the ISO 5 Laminar Flow Hood (LFH). You also use nonsterile, low lint pads when you perform a "Surface Safe" cleaning of each BSC, which includes applying <Redacted B4> disinfectant cleaner to the interior of each BSC. In addition, you use non-sterile, low lint pads when you perform a "Surface Safe" cleaning of the LFH, which includes applying non-sterile <Redacted B4> disinfectant to the interior of the LFH.
Observation 5
The use of sporicidal agents in the cleamooms and ISO 5 classified aseptic processing area was inadequate.
Specifically, you have not defined a required contact time for each of the disinfectant solutions used to disinfect the <Redacted B4> ISO 5 BSCs, ISO 5 LFH and ISO 7 areas of the production areas. Pha1macy personnel who perform cleaning and disinfectant operations did not follow the disinfectant manufacturer's recommended contact time for <Redacted B4> . In addition, pharmacy personnel do not document the disinfectant contact time when they perform cleaning and disinfecting operations.
Observation 6
The ISO 7 classified areas have difficult to clean, particle -generating equipment or surfaces.
Specifically, you installed <Redacted B4> stems" in our production area, • ISO 7 <Redacted B4> and <Redacted B4> personnel do not have access to clean and disinfect the interior of the units dunng routine cleaning and disinfecting operations of the ISO 7 classified rooms. In addition, you have failed to demonstrate that each of the -units can be properly cleaned and disinfected and failed to demonstrate that each unit does not generate particulates in the ISO 7 classified areas.
Observation 7
ISO 5 Areas are not certified under dynamic conditions.
Specifically, you did not demonstrate laminar, uni-directional airflow over critical zones under dynamic conditions meant to simulate aseptic manipulations during smoke pattern testing of the <Redacted B4> ISO 5 Biological Safety Cabinets (BSCs), and the ISO 5 Laminar Flow Hood (LFH), <Redacted B4>. For example, reports of smoke pattern testing conducted on 06/12/2019, 12/12/2018 and 06/13/2018 failed to describe the equipment set up within each hood and the specific operations to be performed during smoke pattern testing and failed to determine if all critical and worse case operations were performed and captured. In addition, there is no evidence indicating the certifications reports were reviewed, evaluated and accepted by pharmacy personnel.
State board of pharmacy records
State board of pharmacy records for Rhode Island are not checked: this index has not yet added that board’s records.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.